Výsledky vyhledávání - "Nuwan Kurukulasuriya"

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

Autor: Robert J. Fox, Michael Hutchinson, Carlo Pozzilli, Eva Havrdova, K. Selmaj, Ralf Gold, David G. MacManus, Theodore Phillips, James Potts, Minhua Yang, Tarek A. Yousry, Mark Novas, Douglas L. Arnold, Nuwan Kurukulasuriya, Marianne T. Sweetser, Ludwig Kappos, Ray Zhang, Amit Bar-Or, David Miller

Publikováno v: Multiple Sclerosis (Houndmills, Basingstoke, England)

Background: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile for patients with relapsing–remitting multiple sclerosis (RRMS) in phase 3 DEFINE/CONFIRM studies. ENDORSE is an ongoing long-te

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f78ef34d45e60a75761dd3357f9937
http://europepmc.org/articles/PMC5418934

Zobrazit plný text záznamu

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

Autor: Norman Kim, Marianne T. Sweetser, Patricia Valencia, J. Theodore Phillips, Tim Thullen, Nuwan Kurukulasuriya, Lauren Oliva, Ludwig Kappos, Vissia Viglietta, Robert J. Fox, Amit Bar-Or, Jie Li, Mark Novas, Eva Havrdova, Ralf Gold

Publikováno v: Neurology and Therapy

Introduction Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) is an oral agent for the treatment of relapsing forms of multiple sclerosis (MS). No formal studies of DMF were conducted in pregnant women, although pregnancies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce364f296eb8857de18f55012f1f98a
http://europepmc.org/articles/PMC4685863

Zobrazit plný text záznamu

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)

Autor: Leslie Meltzer, J. Theodore Phillips, Nuwan Kurukulasuriya, Gavin Giovannoni, Robert J. Fox, Annie Zhang, Ralf Gold

Publikováno v: Multiple Sclerosis (Houndmills, Basingstoke, England)

Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety in the Phase 3 DEFINE and CONFIRM trials. Objective: To evaluate delayed-release DMF in newly diagnosed relapsing–remitting multiple sclerosis (RRMS) patients, in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9cb7eabc7d8e0d800021e763cb8bd54
https://doi.org/10.1177/1352458514537013

Zobrazit plný text záznamu

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

Autor: Robert J. Fox, Michael Hutchinson, Nuwan Kurukulasuriya, Ankush Taneja, M.K. Siddiqui, Sonalee Agarwal, Baris Deniz, Eva Havrdova, Sujata P. Sarda

Publikováno v: Current Medical Research and Opinion. 30:613-627

Currently, direct comparative evidence or head-to-head data between BG-12 (dimethyl fumarate) and other disease-modifying treatments (DMTs) is limited. This study is a systematic review and data synthesis of published randomized clinical trials compa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b49298b03c8af77db33a2a90ccd56b28
https://doi.org/10.1185/03007995.2013.863755

Zobrazit plný text záznamu

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

Autor: Eva Havrdova, Michael Hutchinson, Ralf Gold, Marianne T. Sweetser, Katherine Dawson, Nuwan Kurukulasuriya, Kartik Raghupathi

Publikováno v: Expert Opinion on Pharmacotherapy. 14:2145-2156

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide.This article aims to summarize the finding

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feaa7f03888a2d998ac81c6f8b666c5d
https://doi.org/10.1517/14656566.2013.826190

Zobrazit plný text záznamu

Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis

Autor: Matthew Scaramozza, Nuwan Kurukulasuriya, Hans-Peter Hartung, Steven J. Greenberg, Giancarlo Comi

Publikováno v: Expert opinion on pharmacotherapy. 14(1)

Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f698334b158ff8e4aaaf06e3ad078e1d
https://pubmed.ncbi.nlm.nih.gov/23256603

Zobrazit plný text záznamu

Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study

Autor: Stuart D. Cook, Peter Rieckmann, Nuwan Kurukulasuriya, Per Soelberg Sørensen, A Hamlett, Gavin Giovannoni, Kottil Rammohan, Patrick Vermersch, Giancarlo Comi

Publikováno v: Multiple sclerosis and related disorders. 1(1)

In the phase III CLARITY study, treatment with cladribine tablets at cumulative doses of 3.5 or 5.25mg/kg over 96 weeks led to significant reductions in annualized relapse rates (ARR) versus placebo in patients with relapsing-remitting multiple scler

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc82001e5bac88dde62b60ce5a63efce
https://pubmed.ncbi.nlm.nih.gov/25876451

Zobrazit plný text záznamu

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Autor: Jie Li, Nuwan Kurukulasuriya, Glenn Phillips, John O'Gorman, Vissia Viglietta, Heidy Russell

Publikováno v: Clinical Therapeutics. 37:1402-1419.e5

Purpose In Phase III trials, delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated significant efficacy and an acceptable safety profile in patients with relapsing-remitting multiple sclerosis. The purpose of the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5163bc41f698d7fd2b6ed3c37ef363
https://doi.org/10.1016/j.clinthera.2015.03.028

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání